HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer
American Journal of Clinical Pathology · 2024
DOI: 10.1093/ajcp/aqad167 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Daniel Xia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Health Network, Toronto,Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, High-Throughput Nucleotide Sequencing, In Situ Hybridization, Fluorescence. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Specialized Program of Research Excellence, Dana-Farber Cancer Institute Breast Oncology Center, Harvard Cancer Center.
Abstract (Originalsprache)
Objectives
A combination of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is the current standard of care for HER2 evaluation in breast cancer. Here, we investigate the potential clinical utility of next-generation sequencing (NGS)–derived HER2/ERBB2 copy number (CN) data for predicting HER2 status as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
Methods
In total, 294 locally recurrent and metastatic breast cancers previously tested by targeted hybrid capture–based NGS and by HER2 IHC/FISH were included. Analyses focused on the ERBB2 median log2 ratios and start-end genomic coordinates from NGS, average HER2 CN and HER2/CEP17 ratios from FISH, and the HER2 IHC scores. We also determined a more stringent log2 ratio cutoff to predict HER2-positive status with 100% specificity.
Results
Sixty-four (22%) cases were HER2 positive and 230 (78%) were HER2 negative by ASCO/CAP guidelines. The ERBB2 median log2 ratios from NGS strongly correlated with HER2 status by IHC/FISH (area under receiver operator characteristic curve = 0.951). ERBB2 log2 ratio more than 1.7 was 100% specific for HER2-positive results by IHC/FISH. Start and end genomic coordinates for regions of gain near ERBB2 by NGS also predicted HER2 status.
Conclusions
Copy number data from our NGS panel strongly correlate with HER2 status. Using a stringent cutoff, ERBB2 log2 ratio accurately predicts HER2 positivity with high specificity. The NGS CN assessment may have utility in determining HER2 status in certain clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University Health Network, Toronto,Canada.
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, US.
- Breast Oncology, Dana Farber Cancer Institute, Boston, MA, US.
- Pathology & Laboratory Medicine, Weill Cornell Medicine, New York, NY, US.
- Yale Cancer Center, New Haven, CT, US.
ORCID-Profile: Daniel Xia
Förderung
- Specialized Program of Research Excellence
- Dana-Farber Cancer Institute Breast Oncology Center
- Harvard Cancer Center
Zitieren
APA
Xia, D., Kuo, F., Hughes, M., Lindeman, N., Manning, D., Files, J., Strauss, S., Kirkner, G., Mohammed-Abreu, A., Winer, E., Tolaney, S. M., Lin, N. U., & Dillon, D. A. (2024). HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad167
Vancouver
Xia D, Kuo F, Hughes M, Lindeman N, Manning D, Files J, et al. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad167
BibTeX
@article{Xia2024,
author = {Xia, Daniel and Kuo, Frank and Hughes, Melissa and Lindeman, Neal and Manning, Danielle and Files, Janet and Strauss, Sarah and Kirkner, Greg and Mohammed-Abreu, Ayesha and Winer, Eric and Tolaney, Sara M and Lin, Nancy U and Dillon, Deborah A},
title = {HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer},
journal = {American Journal of Clinical Pathology},
year = {2024},
doi = {10.1093/ajcp/aqad167}
}
EUVIMED